Nanoparticles for the regulation of intestinal inflammation: opportunities and challenges
Prevalence of chronic inflammation of the gastrointestinal tract is increasing, emerging as a public health challenge. Conventional drug delivery systems targeting the colon have improved the treatment of inflammatory bowel disease. However, therapy frequently results in inconsistent efficacy and to...
Gespeichert in:
| Veröffentlicht in: | Nanomedicine (London, England) England), 2019-10, Vol.14 (19), p.2631-2644 |
|---|---|
| Hauptverfasser: | , , |
| Format: | Artikel |
| Sprache: | eng |
| Schlagworte: | |
| Online-Zugang: | Volltext |
| Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
| container_end_page | 2644 |
|---|---|
| container_issue | 19 |
| container_start_page | 2631 |
| container_title | Nanomedicine (London, England) |
| container_volume | 14 |
| creator | Nunes, Rute Neves, José das Sarmento, Bruno |
| description | Prevalence of chronic inflammation of the gastrointestinal tract is increasing, emerging as a public health challenge. Conventional drug delivery systems targeting the colon have improved the treatment of inflammatory bowel disease. However, therapy frequently results in inconsistent efficacy and toxicity problems. Novel approaches based on nanoparticles offer several advantages over conventional dosage forms due to their ability to selectively target inflamed tissues. Several formulation efforts have been made in order to obtain increasingly selective nanosized systems, some with promising results in animal models of colitis. Despite all advances, no nanomedicines are yet approved for clinical use in inflammatory bowel disease. This review discusses the most recent efforts made toward the development of nanoparticles for regulating chronic intestinal inflammation. |
| doi_str_mv | 10.2217/nnm-2019-0191 |
| format | Article |
| fullrecord | <record><control><sourceid>proquest_cross</sourceid><recordid>TN_cdi_proquest_miscellaneous_2305799667</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><sourcerecordid>2312478289</sourcerecordid><originalsourceid>FETCH-LOGICAL-c371t-3bbcfd245f6f9ad46f73202fa4011411c2040965f535729c6fa6650f619840c73</originalsourceid><addsrcrecordid>eNp1kDtPBCEURonRuOujtDWT2NiM8piBwc5sfCVGGy2sCMuCYhgYgSn89zLuamFiQbjknvuFewA4QvAMY8TOve9rDBGvy0FbYI5Y09WUU7L9XZO67To-A3spvUPYdhjBXTAjiCLMGJmDlwfpwyBjtsrpVJkQq_ymq6hfRyezDb4KprI-65Stl66Uxsm-_25dVGEYQsyjt9mWYelXlXqTzmn_qtMB2DHSJX24uffB8_XV0-K2vn-8uVtc3teKMJRrslwqs8JNa6jhctVQwwiG2MgGItQgpDBsIKetaUnLMFfUSEpbaCjiXQMVI_vgdJ07xPAxln-K3ialnZNehzEJTGDLOKd0Qk_-oO9hjGWtiUK4YR3ueKHqNaViSClqI4Zoexk_BYJici6KczE5F5Pzwh9vUsdlr1e_9I_kAvA1YMY8Rp2U1V5psX6VCaus1_-EfwHDXpA_</addsrcrecordid><sourcetype>Aggregation Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>2312478289</pqid></control><display><type>article</type><title>Nanoparticles for the regulation of intestinal inflammation: opportunities and challenges</title><source>PubMed Central</source><creator>Nunes, Rute ; Neves, José das ; Sarmento, Bruno</creator><creatorcontrib>Nunes, Rute ; Neves, José das ; Sarmento, Bruno</creatorcontrib><description>Prevalence of chronic inflammation of the gastrointestinal tract is increasing, emerging as a public health challenge. Conventional drug delivery systems targeting the colon have improved the treatment of inflammatory bowel disease. However, therapy frequently results in inconsistent efficacy and toxicity problems. Novel approaches based on nanoparticles offer several advantages over conventional dosage forms due to their ability to selectively target inflamed tissues. Several formulation efforts have been made in order to obtain increasingly selective nanosized systems, some with promising results in animal models of colitis. Despite all advances, no nanomedicines are yet approved for clinical use in inflammatory bowel disease. This review discusses the most recent efforts made toward the development of nanoparticles for regulating chronic intestinal inflammation.</description><identifier>ISSN: 1743-5889</identifier><identifier>EISSN: 1748-6963</identifier><identifier>DOI: 10.2217/nnm-2019-0191</identifier><identifier>PMID: 31612773</identifier><language>eng</language><publisher>England: Future Medicine Ltd</publisher><subject>Colon ; colon-targeted drug delivery ; Colorectal cancer ; Crohn's disease ; Drug delivery systems ; Drug dosages ; Enzymes ; Gastroenterology ; Inflammation ; Inflammatory bowel disease ; Microbiota ; Nanocomposites ; Nanoparticles ; Permeability ; ulcerative colitis</subject><ispartof>Nanomedicine (London, England), 2019-10, Vol.14 (19), p.2631-2644</ispartof><rights>2019 Future Medicine Ltd</rights><rights>Copyright Future Medicine Ltd Oct 2019</rights><lds50>peer_reviewed</lds50><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c371t-3bbcfd245f6f9ad46f73202fa4011411c2040965f535729c6fa6650f619840c73</citedby><cites>FETCH-LOGICAL-c371t-3bbcfd245f6f9ad46f73202fa4011411c2040965f535729c6fa6650f619840c73</cites></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><link.rule.ids>314,780,784,27924,27925</link.rule.ids><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/31612773$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Nunes, Rute</creatorcontrib><creatorcontrib>Neves, José das</creatorcontrib><creatorcontrib>Sarmento, Bruno</creatorcontrib><title>Nanoparticles for the regulation of intestinal inflammation: opportunities and challenges</title><title>Nanomedicine (London, England)</title><addtitle>Nanomedicine (Lond)</addtitle><description>Prevalence of chronic inflammation of the gastrointestinal tract is increasing, emerging as a public health challenge. Conventional drug delivery systems targeting the colon have improved the treatment of inflammatory bowel disease. However, therapy frequently results in inconsistent efficacy and toxicity problems. Novel approaches based on nanoparticles offer several advantages over conventional dosage forms due to their ability to selectively target inflamed tissues. Several formulation efforts have been made in order to obtain increasingly selective nanosized systems, some with promising results in animal models of colitis. Despite all advances, no nanomedicines are yet approved for clinical use in inflammatory bowel disease. This review discusses the most recent efforts made toward the development of nanoparticles for regulating chronic intestinal inflammation.</description><subject>Colon</subject><subject>colon-targeted drug delivery</subject><subject>Colorectal cancer</subject><subject>Crohn's disease</subject><subject>Drug delivery systems</subject><subject>Drug dosages</subject><subject>Enzymes</subject><subject>Gastroenterology</subject><subject>Inflammation</subject><subject>Inflammatory bowel disease</subject><subject>Microbiota</subject><subject>Nanocomposites</subject><subject>Nanoparticles</subject><subject>Permeability</subject><subject>ulcerative colitis</subject><issn>1743-5889</issn><issn>1748-6963</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2019</creationdate><recordtype>article</recordtype><sourceid>ABUWG</sourceid><sourceid>AFKRA</sourceid><sourceid>BENPR</sourceid><sourceid>CCPQU</sourceid><recordid>eNp1kDtPBCEURonRuOujtDWT2NiM8piBwc5sfCVGGy2sCMuCYhgYgSn89zLuamFiQbjknvuFewA4QvAMY8TOve9rDBGvy0FbYI5Y09WUU7L9XZO67To-A3spvUPYdhjBXTAjiCLMGJmDlwfpwyBjtsrpVJkQq_ymq6hfRyezDb4KprI-65Stl66Uxsm-_25dVGEYQsyjt9mWYelXlXqTzmn_qtMB2DHSJX24uffB8_XV0-K2vn-8uVtc3teKMJRrslwqs8JNa6jhctVQwwiG2MgGItQgpDBsIKetaUnLMFfUSEpbaCjiXQMVI_vgdJ07xPAxln-K3ialnZNehzEJTGDLOKd0Qk_-oO9hjGWtiUK4YR3ueKHqNaViSClqI4Zoexk_BYJici6KczE5F5Pzwh9vUsdlr1e_9I_kAvA1YMY8Rp2U1V5psX6VCaus1_-EfwHDXpA_</recordid><startdate>20191001</startdate><enddate>20191001</enddate><creator>Nunes, Rute</creator><creator>Neves, José das</creator><creator>Sarmento, Bruno</creator><general>Future Medicine Ltd</general><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>3V.</scope><scope>7X7</scope><scope>7XB</scope><scope>88E</scope><scope>8AO</scope><scope>8FI</scope><scope>8FJ</scope><scope>8FK</scope><scope>ABUWG</scope><scope>AFKRA</scope><scope>BENPR</scope><scope>CCPQU</scope><scope>EHMNL</scope><scope>FYUFA</scope><scope>GHDGH</scope><scope>K9.</scope><scope>M0S</scope><scope>M1P</scope><scope>PQEST</scope><scope>PQQKQ</scope><scope>PQUKI</scope><scope>PRINS</scope><scope>7X8</scope></search><sort><creationdate>20191001</creationdate><title>Nanoparticles for the regulation of intestinal inflammation: opportunities and challenges</title><author>Nunes, Rute ; Neves, José das ; Sarmento, Bruno</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c371t-3bbcfd245f6f9ad46f73202fa4011411c2040965f535729c6fa6650f619840c73</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2019</creationdate><topic>Colon</topic><topic>colon-targeted drug delivery</topic><topic>Colorectal cancer</topic><topic>Crohn's disease</topic><topic>Drug delivery systems</topic><topic>Drug dosages</topic><topic>Enzymes</topic><topic>Gastroenterology</topic><topic>Inflammation</topic><topic>Inflammatory bowel disease</topic><topic>Microbiota</topic><topic>Nanocomposites</topic><topic>Nanoparticles</topic><topic>Permeability</topic><topic>ulcerative colitis</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Nunes, Rute</creatorcontrib><creatorcontrib>Neves, José das</creatorcontrib><creatorcontrib>Sarmento, Bruno</creatorcontrib><collection>PubMed</collection><collection>CrossRef</collection><collection>ProQuest Central (Corporate)</collection><collection>Health & Medical Collection</collection><collection>ProQuest Central (purchase pre-March 2016)</collection><collection>Medical Database (Alumni Edition)</collection><collection>ProQuest Pharma Collection</collection><collection>Hospital Premium Collection</collection><collection>Hospital Premium Collection (Alumni Edition)</collection><collection>ProQuest Central (Alumni) (purchase pre-March 2016)</collection><collection>ProQuest Central (Alumni Edition)</collection><collection>ProQuest Central UK/Ireland</collection><collection>ProQuest Central</collection><collection>ProQuest One Community College</collection><collection>UK & Ireland Database</collection><collection>Health Research Premium Collection</collection><collection>Health Research Premium Collection (Alumni)</collection><collection>ProQuest Health & Medical Complete (Alumni)</collection><collection>Health & Medical Collection (Alumni Edition)</collection><collection>Medical Database</collection><collection>ProQuest One Academic Eastern Edition (DO NOT USE)</collection><collection>ProQuest One Academic</collection><collection>ProQuest One Academic UKI Edition</collection><collection>ProQuest Central China</collection><collection>MEDLINE - Academic</collection><jtitle>Nanomedicine (London, England)</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Nunes, Rute</au><au>Neves, José das</au><au>Sarmento, Bruno</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Nanoparticles for the regulation of intestinal inflammation: opportunities and challenges</atitle><jtitle>Nanomedicine (London, England)</jtitle><addtitle>Nanomedicine (Lond)</addtitle><date>2019-10-01</date><risdate>2019</risdate><volume>14</volume><issue>19</issue><spage>2631</spage><epage>2644</epage><pages>2631-2644</pages><issn>1743-5889</issn><eissn>1748-6963</eissn><abstract>Prevalence of chronic inflammation of the gastrointestinal tract is increasing, emerging as a public health challenge. Conventional drug delivery systems targeting the colon have improved the treatment of inflammatory bowel disease. However, therapy frequently results in inconsistent efficacy and toxicity problems. Novel approaches based on nanoparticles offer several advantages over conventional dosage forms due to their ability to selectively target inflamed tissues. Several formulation efforts have been made in order to obtain increasingly selective nanosized systems, some with promising results in animal models of colitis. Despite all advances, no nanomedicines are yet approved for clinical use in inflammatory bowel disease. This review discusses the most recent efforts made toward the development of nanoparticles for regulating chronic intestinal inflammation.</abstract><cop>England</cop><pub>Future Medicine Ltd</pub><pmid>31612773</pmid><doi>10.2217/nnm-2019-0191</doi><tpages>14</tpages></addata></record> |
| fulltext | fulltext |
| identifier | ISSN: 1743-5889 |
| ispartof | Nanomedicine (London, England), 2019-10, Vol.14 (19), p.2631-2644 |
| issn | 1743-5889 1748-6963 |
| language | eng |
| recordid | cdi_proquest_miscellaneous_2305799667 |
| source | PubMed Central |
| subjects | Colon colon-targeted drug delivery Colorectal cancer Crohn's disease Drug delivery systems Drug dosages Enzymes Gastroenterology Inflammation Inflammatory bowel disease Microbiota Nanocomposites Nanoparticles Permeability ulcerative colitis |
| title | Nanoparticles for the regulation of intestinal inflammation: opportunities and challenges |
| url | https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2024-12-21T15%3A51%3A55IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_cross&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Nanoparticles%20for%20the%20regulation%20of%20intestinal%20inflammation:%20opportunities%20and%20challenges&rft.jtitle=Nanomedicine%20(London,%20England)&rft.au=Nunes,%20Rute&rft.date=2019-10-01&rft.volume=14&rft.issue=19&rft.spage=2631&rft.epage=2644&rft.pages=2631-2644&rft.issn=1743-5889&rft.eissn=1748-6963&rft_id=info:doi/10.2217/nnm-2019-0191&rft_dat=%3Cproquest_cross%3E2312478289%3C/proquest_cross%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=2312478289&rft_id=info:pmid/31612773&rfr_iscdi=true |